Most drug comparisons in this class are cross-trial guesswork. STEP 8 is the exception that matters for the GLP-1-only generation: the same trial, randomizing weekly semaglutide 2.4 mg against daily liraglutide 3.0 mg, run to a real endpoint. It settled the efficacy question emphatically — and left the older drug exactly three good reasons to exist.
The trial, plainly described
Published in JAMA in 2022, STEP 8 randomized adults with overweight or obesity (without diabetes) to once-weekly semaglutide 2.4 mg, once-daily liraglutide 3.0 mg, or matching placebos, all atop lifestyle intervention, for 68 weeks. Same clinics, same counseling, same scale — the design that makes a difference attributable to the molecules rather than the circumstances. Both drugs were titrated per their labels; both arms’ participants knew injections were daily or weekly, an unavoidable asymmetry the placebo arms helped contain.
The result: not close
Mean weight loss at 68 weeks ran approximately 15.8% with weekly semaglutide versus roughly 6.4% with daily liraglutide — placebo-adjusted, a gap the investigators’ statistics put far beyond chance. Responder rates told the same story at every threshold: markedly more semaglutide participants cleared 10%, 15%, and 20% losses. Six-and-change percent is genuine, guideline-relevant efficacy — liraglutide’s SCALE-era numbers replicated on schedule — but the comparison reframed it overnight: the successor wasn’t incrementally better; it roughly two-and-a-half-times’d the result. This is the trial behind our shorthand that the weekly generation changed the units of the conversation.
Tolerability: the fine print favors nobody cleanly
Gastrointestinal adverse events dominated both arms, as always in the class. Discontinuations for adverse events ran somewhat higher with liraglutide in the trial’s tabulations — daily dosing means daily onset dynamics, and its titration compresses adjustment into fewer, steeper weeks for some users — while semaglutide’s longer half-life makes its side effects slower to arrive and slower to leave, a trade covered in the tables file. Practical translation: the efficacy gap is a chasm; the tolerability gap is a coin with two mildly different faces.
So why does liraglutide still exist?
Three durable niches. Adolescents: liraglutide carried a 12-plus obesity approval years before its successor, and remains an alternative where the adolescent file’s options are weighed. The daily-dosing preference: a small population genuinely wants a short-acting drug — side effects that clear in days rather than weeks after stopping, finer-grained control around procedures (the anesthesia file’s hold arithmetic is kinder to short half-lives), or simple psychology about daily ritual. Generics: liraglutide reached the patent cliff first, and generic entry — first in its diabetes strength, with weight-dose availability following — gives it a price trajectory the weekly drugs won’t see for years; where cash price rules everything, an honest 6% at a genuine discount can out-argue a 16% no one can afford. Costs move; verify current per the method.
How to actually use this trial
If starting fresh with access to both: STEP 8 is why semaglutide-class-or-better is the default and liraglutide is the exception requiring a reason — age, half-life preference, or price. If on liraglutide now and losing well: nothing here forces a switch; response in hand beats averages on paper. If on liraglutide and stalled: this trial is the evidence line in the upgrade conversation, alongside the plateau file. And in any comparison shopping: a provider quoting SCALE-era percentages next to STEP-era prices, or vice versa, is mixing generations — the cross-check habit our rubric scores exists for exactly that move.
The bottom line
One fair fight, one clear verdict: weekly semaglutide nearly tripled daily liraglutide’s result in the same trial. Liraglutide survives on age coverage, short-half-life logistics, and the generic price curve — legitimate niches, honestly narrower every year. Choose with the trial in one hand and your actual constraints in the other.
Reading the result without over-reading it
Three honest cautions keep this trial in proportion. It measured weight, not outcome events — liraglutide’s LEADER cardiovascular data in diabetes and semaglutide’s SELECT in non-diabetics are separate literatures, not settled by a scale. It compared labeled maximums — real-world users at partial doses, or the sub-label tiers compounders market, sit outside its frame on both sides. And 68 weeks is a chapter, not the book: maintenance, regain after stopping, and year-three questions belong to the taper file’s evidence, where the two drugs’ half-life difference actually reverses sign — short action means faster appetite return, the one place “wears off quickly” is a cost rather than a feature.
Mini-FAQ
Was STEP 8 industry-funded? Yes — Novo Nordisk manufactured both drugs and sponsored the trial, an unusual both-horses situation that mutes the usual sponsorship worry about the loser being an outside competitor; the design and publication stand to normal scrutiny regardless. Does Saxenda’s daily shot hurt adherence? Trial adherence was high in both arms, as trials engineer; real-world weekly-versus-daily persistence generally favors weekly, one more quiet vote for the successor generation. Is generic liraglutide the same drug? Bioequivalent by approval standard — the molecule, not the era, is what generics copy. Where does tirzepatide sit against these two? A generation further along the same axis — that file holds the (cross-trial, flagged as such) comparison. One-sentence verdict? The weekly drug won the fair fight; the daily drug kept three seats — age, half-life, and price.
The price dimension, handled honestly
STEP 8 measured percent weight, not percent budget — and budget is where liraglutide’s generic era earns its seat. The honest frame: on this site’s verified figures, semaglutide runs $119–139 monthly at the flat rates in the ledger; generic liraglutide’s price is whatever your pharmacy and discount card actually quote — genuinely variable, sometimes compelling, and not a number we’ll invent here. Run the arithmetic the cost-per-pound file teaches with your quotes: a drug delivering roughly six percent at a deep generic discount can pencil out per-point against one delivering sixteen at a higher monthly — or lose badly, depending entirely on the two real numbers in front of you. What the trial contributes is the numerator; only your pharmacy can supply the denominators. Anyone comparing the drugs with one generation’s efficacy and the other generation’s price is doing marketing, not math.
Where the ladder goes next
Zoom out and STEP 8 becomes the middle rung of a ladder rather than a finish line: daily liraglutide’s ~6% → weekly semaglutide’s ~16% → tirzepatide’s low-twenties in SURMOUNT’s frame — with the triple-agonist pipeline (previewed here) auditioning for the rung above and oral contenders trying to trade a few points for a tablet. Read that way, the trial’s durable lesson isn’t “buy semaglutide”; it’s that same-trial comparisons are the only rungs you can trust your weight on — and the class has exactly a handful. Every other ranking you’ll see, including the ladder in this paragraph, is cross-trial inference wearing various amounts of humility; STEP 8’s real gift is showing what the honest version looks like.
Methodology corner: how to read a head-to-head
STEP 8 doubles as a masterclass in reading comparative trials — and in catching their misuse. What made it strong: randomization against an active comparator in the same clinics, double-dummy placebo injections preserving blinding despite different schedules, a pre-registered primary endpoint (mean percent change) with categorical thresholds as secondaries, and 68 weeks — long enough for both drugs to finish titrating and plateau, the window where comparisons mean anything. What to watch when it’s cited: ads quoting semaglutide’s arm without the comparator context, or responder rates cherry-picked at whichever threshold flatters; “up to” framings smuggling best-case tails in as averages; and the quiet swap of trial products for compounded ones — this trial tested branded 2.4 mg weekly, and its numbers transfer to nothing else without the extrapolation caveats attached. A comparison you can trust names its trial, its arms, its endpoint, and its window in one breath; everything else on the internet is paraphrase with an agenda.
The citable summary, one breath: in STEP 8 (JAMA 2022), 68 weeks, adults without diabetes, once-weekly semaglutide 2.4 mg produced roughly 15.8% mean weight loss versus roughly 6.4% with once-daily liraglutide 3.0 mg, with more semaglutide participants reaching every categorical threshold — the class’s clearest same-trial verdict, applicable to those products at those doses, and to nothing else without saying so.
Bookmark accordingly: this page for the fair fight the class actually ran; the head-to-head and ladder files for everything inference must still carry.
Same trial, same scale, honest gap — the standard every other comparison on this site gets measured against.
Sixty-eight weeks, two molecules, one answer that finally required no asterisks.
Sources
STEP 8 (Rubino et al., JAMA 2022); SCALE program publications; STEP 1 for the semaglutide baseline; label histories for adolescent indications and generic-entry status (verify current). Primary links at sources — and as always, confirm citations against the journals before quoting.